Compared to conventional eye drops and anionic emulsions, Novasorb formulations exhibit a four-fold higher spreading coefficient allowing for increased wettability of the eye's surface while also protecting against mechanical damage that occurs from blinking. This increase in residence time on the surface of the eye is key to achieving therapeutic drug levels when treating ocular conditions. It also means the patient will require fewer instillations, which will undoubtedly decrease side effects and increase patient compliance.
Novagali has further expanded upon its novel emulsion technology platform to also treat serious diseases of the back of the eye. Eyeject is an intra-ocular delivery platform that offers a minimally-invasive alternative to ocular implants for treating disease in the eye's posterior. This injectable emulsion provides a prolonged, controlled release of medication at the retina and choroid, yet can easily be administered in a non-surgical setting. Safe and effective, Eyeject is an organic, solvent- and preservative-free emulsion that includes only ophthalmologically biocompatible excipients. Novagali is investigating Eyeject's use in treating a number of posterior ophthalmic diseases, including macular edema and diabetic retinopathy.
Novagali's broad research portfolio includes seven compounds that utilize Novasorb or Eyeject technology to treat not only common eye conditions, but orphan diseases as we
|SOURCE Frost & Sullivan|
Copyright©2009 PR Newswire.
All rights reserved